Kalydeco* (ivacaftor) vs Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Kalydeco* (ivacaftor) vs Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Kalydeco (ivacaftor) is a CFTR potentiator designed to enhance the function of the CFTR protein once it reaches the cell surface, primarily effective in cystic fibrosis (CF) patients with specific genetic mutations. Trikafta, a combination of elexacaftor, tezacaftor, and ivacaftor, works by correcting the processing and function of the faulty CFTR protein, leading to an improvement in CFTR function at the cell surface; it is indicated for a broader range of CF mutations compared to Kalydeco. When deciding between Kalydeco and Trikafta, it is essential to consider the specific CFTR mutations a patient has, as Trikafta can treat individuals with at least one F508del mutation, which is the most common, while Kalydeco is for a select group of other mutations.
Difference between Kalydeco* and Trikafta*
| Metric | Kalydeco* (ivacaftor) | Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor) |
|---|---|---|
| Generic name | Ivacaftor | Elexacaftor/tezacaftor/ivacaftor |
| Indications | Cystic fibrosis in patients with specific mutations in the CFTR gene | Cystic fibrosis in patients aged 12 years and older with at least one F508del mutation in the CFTR gene |
| Mechanism of action | CFTR potentiator | CFTR modulator (combination of potentiator and correctors) |
| Brand names | Kalydeco | Trikafta |
| Administrative route | Oral | Oral |
| Side effects | Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, nausea, dizziness | Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, nausea, dizziness, increased liver enzymes |
| Contraindications | Use with certain drugs that are strong CYP3A inducers or inhibitors | Use with certain drugs that are strong CYP3A inducers or inhibitors |
| Drug class | CFTR potentiator | CFTR modulator |
| Manufacturer | Vertex Pharmaceuticals | Vertex Pharmaceuticals |
Efficacy
Kalydeco (Ivacaftor) Efficacy in Cystic Fibrosis
Kalydeco (ivacaftor) is a medication approved for the treatment of cystic fibrosis (CF) in patients aged 6 months and older who have one of several specific mutations in the CFTR gene. The efficacy of Kalydeco in cystic fibrosis has been demonstrated in clinical trials where it has been shown to improve lung function, as measured by the percent predicted forced expiratory volume in one second (ppFEV1). Patients taking Kalydeco have experienced significant improvements in lung function compared to those on placebo.
Additionally, Kalydeco has been associated with other health benefits for CF patients, including a reduction in pulmonary exacerbations, which are periods when respiratory symptoms worsen significantly. It has also been linked to weight gain and improvements in body mass index (BMI), which are important indicators of overall health in CF patients, who often struggle with malnutrition and difficulty maintaining a healthy weight.
Trikafta (Elexacaftor/Tezacaftor/Ivacaftor) Efficacy in Cystic Fibrosis
Trikafta, a combination of elexacaftor, tezacaftor, and ivacaftor, represents a significant advancement in the treatment of cystic fibrosis. It is approved for use in patients aged 6 years and older who have at least one F508del mutation in the CFTR gene, which is the most common mutation causing CF. Clinical trials have shown that Trikafta substantially improves lung function, with patients experiencing an average increase in ppFEV1 that is clinically meaningful. This improvement in lung function is a strong indication of the drug's efficacy in treating the respiratory aspects of CF.
In addition to enhancing lung function, Trikafta has shown efficacy in improving other outcomes for CF patients. The medication has been associated with a decrease in the rate of pulmonary exacerbations and improvements in respiratory symptoms. Furthermore, patients on Trikafta have reported better quality of life scores, indicating that the drug not only addresses the physical aspects of the disease but also has a positive impact on patients' overall well-being.
Regulatory Agency Approvals
Kalydeco*
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Trikafta*
-
Food and Drug Administration (FDA), USA
Access Kalydeco* or Trikafta* today
If Kalydeco* or Trikafta* are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us